Yarrow Bioscience (YARW) Receivables - Other (2020 - 2021)
Yarrow Bioscience's (YARW) quarterly Receivables - Other came in at $5.5 million in Q4 2021, down 5.17% on a YoY basis from $5.8 million in Q4 2020, and down 24.66% quarter-over-quarter from $7.3 million in Q3 2021.
Powered by 
Analysis
Yarrow Bioscience (YARW) Receivables - Other (2020 - 2021) Analysis & Trends
Yarrow Bioscience (YARW) has reported Receivables - Other for 2 consecutive years, with $5.5 million the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Receivables - Other fell 5.17% year-over-year to $5.5 million; the trailing twelve-month figure through Dec 2021 stood at $5.5 million (down 5.17% YoY), and the FY2021 full-year result was $5.5 million, down 5.17% from the prior year.
- Receivables - Other retreated to $5.5 million in Q4 2021 per YARW's latest filing, from $7.3 million in the prior quarter.
- Across five years, Receivables - Other topped out at $8.1 million in Q1 2021 and bottomed at $4.0 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Yarrow Bioscience | 25.92 Mn | 3.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 5.50 Mn |
| Sep 30, 2021 | 7.30 Mn |
| Jun 30, 2021 | 7.60 Mn |
| Mar 31, 2021 | 8.10 Mn |
| Dec 31, 2020 | 5.80 Mn |
| Sep 30, 2020 | 5.60 Mn |
| Jun 30, 2020 | 4.00 Mn |